**SDC 3.** Levofloxacin pharmacokinetic parameters for study participants with MDR LTBI on levofloxacin and ethambutol or levofloxacin alone, Federated States of Micronesia (FSM), and Republic of the Marshall Islands (RMI), 2009–2011.

|  |  |  |
| --- | --- | --- |
| **Parameter** | **FSM (N=25[[1]](#footnote-1))** | **RMI (N= 17)** |
| **Cmax, mean**±**SD** |  |  |
| Levofloxacin | 7·55±4·62 | --- |
| Levofloxacin/Ethambutol | 7·68±2·15 | 8·71±2·09 |
| **t1/2, mean**±**SD** |  |  |
| Levofloxacin | 4·20±2·18 | --- |
| Levofloxacin/Ethambutol | 4·89±2·97 | 4·99±1·73 |
| **Tmax, mean**±**SD** |  |  |
| Levofloxacin | 1·41±0·51 | --- |
| Levofloxacin/Ethambutol | 1·13±0·35 | 1·41±0·51 |
| **AUC0-6, mean**±**SD** |  |  |
| Levofloxacin | 30·22±19·36 | --- |
| Levofloxacin/Ethambutol | 29·88±8·09 | 37·22±7·76 |

1. Eight of 33 patients in FSM were treated with multiple medications including levofloxacin as MDR TB cases [↑](#footnote-ref-1)